A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer

NCT05557565 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer

Interventions

DRUG: QL1706

Sponsor

Qilu Pharmaceutical Co., Ltd.